INCLINE VILLAGE, Nev., Sept. 9 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference in New York City on Wednesday, September 16, 2009 at 11:00 a.m. Eastern Time.
About PDL BioPharma, Inc.
PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.
SOURCE PDL BioPharma, Inc.
CONTACT: Danielle Bertrand of WeissComm Partners, +1-415-946-1056,
dbertrand@wcpglobal.com, for PDL BioPharma, Inc.
Web site: http://www.pdl.com/
